Pfizer exceeds profit estimates in Q1 2025 despite declining sales, with cost-cutting efforts ongoing.

From CNBC: 2025-04-29 09:55:00

In Q1 of 2025, Pfizer exceeded profit estimates despite declining sales due to Paxlovid revenue drop. The company expects $4.5 billion in cost savings by 2025, with an additional $1.2 billion by 2027 through digital enhancement and R&D reorganization. With ongoing cost-cutting efforts, Pfizer aims to achieve $7.7 billion in savings by 2027.

Pfizer continues to face challenges, including potential impact from President Trump’s planned tariffs on pharmaceutical imports. Despite this, the company maintains its full-year 2025 outlook with sales forecasted at $61-$64 billion. Pfizer has established strategies to mitigate potential tariff impact and remains agile in navigating the volatile external environment.

Pfizer anticipates Medicare program changes to reduce sales by $1 billion in 2025. Adjusted earnings per share are expected to range from $2.80 to $3. The company remains focused on maintaining business strength and agility amidst uncertainty. For Q1, Pfizer reported net income of $2.97 billion and revenue of $13.72 billion, down 8% year-over-year.



Read more at CNBC: Pfizer (PFE) earnings Q1 2025